Infanrix-Ipv

Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus vaccine, the active ingredient in Infanrix-Ipv, is a preventive vaccine presented as an injectable solution for intramuscular use. It provides active immunization against diphtheria, tetanus, pertussis and poliomyelitis in infants and young children.

GNH USA supplies Infanrix-Ipv as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Infanrix-Ipv is a combination vaccine that delivers active immunity against bacterial toxins and poliovirus infection.

- Diphtheria: stimulates protective antibodies against diphtheria toxin. - Tetanus: stimulates protective antibodies against tetanus toxin. - Pertussis: stimulates protective antibodies against pertussis toxin, filamentous hemagglutinin and pertactin. - Poliomyelitis: stimulates protective antibodies against poliovirus serotypes 1, 2 and 3.

Common adverse reactions are generally mild and transient.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Irritability: increased fussiness in infants. - Loss of appetite: temporary reduction in feeding. - Fatigue: mild tiredness post‑vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare neurologic events following vaccination. - High fever: temperature >40 °C persisting beyond 24 hours. - Prolonged crying: inconsolable crying lasting more than 3 hours. - Hypotonic‑hyporesponsive episode: transient loss of muscle tone. - Encephalopathy: very rare inflammatory brain condition.

Infanrix-Ipv should be administered according to national immunisation schedules and under professional supervision.

- Age restriction: only for infants and children as specified by health authorities. - Hypersensitivity: avoid in individuals with known allergy to any vaccine component. - Immunodeficiency: use with caution in severely immunocompromised patients. - Schedule adherence: follow recommended dosing intervals to ensure optimal immunity. - Post‑vaccination monitoring: observe for at least 15 minutes for immediate reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other immunologic agents or therapies.

Major Interactions (Avoid): - Live attenuated vaccines: avoid administration within 4 weeks before or after Infanrix-Ipv. - Immunoglobulin therapy: postpone vaccination for at least 3 months after receipt. - Blood products: defer vaccination for 4 weeks following transfusion. - Severe immunosuppressive drugs: may reduce vaccine efficacy. - High‑dose steroids: may blunt immune response.

Moderate Interactions (Monitor Closely): - Antipyretics: may mask fever, monitor temperature independently. - Concurrent vaccines: increased reactogenicity may occur, observe for combined side effects. - Antibiotics: generally no effect, but monitor for unusual reactions. - Allergy medications: may reduce severity of hypersensitivity signs. - Chronic illnesses: assess individual risk‑benefit before vaccination.